During the court proceedings, the originator company pursued four additional infringement suits, alleging the generic product fell within the scope of several different forms and new uses of paroxetine hydrochloride. In case the active ingredient is new and patented in addition to the composition, third parties would not be in a position to legally use the active ingredient without authorization from the patent holder, or through a compulsory license. These considerations do not apply to the treatment of new uses of known products (see above): as opposed to the case of derivatives, new uses concern the identical substance.